Clinicodemographic and tumor characteristics of patients who developed peritoneal metastases following surgical resection for IPMN based on PUBMED-indexed reports up to October 1st, 2019.

Published: 11 August 2022| Version 2 | DOI: 10.17632/mwxcs42hj6.2
Mohammed Suraju,


Prevalence of peritoneal metastases following surgical resection of intraductal papillary mucinous neoplasm (IPMN) are not well known. We hypothesized that higher degree of dysplasia would correlate with higher rates of PM. Clinicodemographic and tumor characteristics in patients who developed peritoneal metastases following surgical resection for IPMN was extracted from PUBMED-indexed articles up to October 1st, 2019. Of 3,580 reported patients that underwent resection for IPMNs across 30 included articles, PM occurred in 117 (3.3%). We found that 4/1884 (0.2%) patients with LGD/IGD developed PM, 13/745 (1.7%) patients with HGD developed PM, while 79/947 (8.3%) patients with invasive carcinoma arising from IPMN developed PM.


Steps to reproduce

PUBMED was queried for all literature published up to October 1st, 2019 with the following key terms: “IPMN AND Recurrence” (362 hits), “IPMN AND Metastatic pancreatic cancer” (243 hits), “IPMN AND Peritoneal carcinomatosis” (35 hits), “IPMN AND Peritoneum” (15 hits), “IPMN AND Peritoneal metastases” (15 hits), “IPMN AND Pseudomyxoma” (12 hits). Inclusion criteria included English articles with report of number of patients with PMs in the setting of IPMN. 30 articles met inclusion criteria. Patients with a history of pancreatic ductal adenocarcinoma (PDAC), and a history of malignancies of other type were excluded. Histologic categories included LGD (previously adenoma), IGD (previously moderate/borderline dysplasia), HGD (previously carcinoma in-situ), and invasive carcinoma arising from IPMN. Atypical hyperplasia was included in the LGD/IGD counts.


Epidemiology, Pancreas, Peritoneum, Intraductal Papillary Mucinous Neoplasm